EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access

First-in-Human Study of IL15–Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia

Eva Rettinger iD, Dirk Heckl iD, Martin Hutter iD, Emilia Salzmann-Manrique, Marie Luedtke, Sabine Huenecke, Melanie Bremm, Claudia Cappel, Gesine Bug iD, Johann Greil iD, Roland Meisel iD, Eva Maria Wagner-Drouet iD und 6 weitere

Journal of Clinical Oncology · 10.05.2026 · 44 (14) · 1323-1336

DOI: 10.1200/jco-25-01966 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2026. Verfasst von Eva Rettinger und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Interleukin-15, Cytokine-Induced Killer Cells, Leukemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with high-risk (HR) leukemia remain at substantial risk of early relapse, treatment-related toxicity, and poor survival, underscoring the need for effective relapse prevention therapies. To our knowledge, this first-in-human, disease burden–guided study evaluated the feasibility, safety, and efficacy of donor-derived allogeneic interleukin-15–activated cytokine-induced killer cells (IL15-CIK) combining T-cell and natural killer cell properties for post-transplant disease control. METHODS In a prospective, multicenter phase I/II trial (EudraCT 2013-005446-11) and an identically designed pilot study, 53 adult and pediatric patients with HR leukemia received 56 courses of IL15-CIK monotherapy after human leukocyte antigen (HLA)–matched or HLA-mismatched transplantation. Treatment intent was categorized as consolidation (13%), preemptive (61%), or salvage (27%) with 169 infusions administered as a single dose (29%) or according to adaptable dose-escalation regimens (71%). RESULTS Acute graft-versus-host disease (GVHD) grades 1-2 and grade 3 occurred in 27% and 4% of cases, respectively; no extensive chronic GVHD or treatment-related mortality was observed. IL15-CIK–associated adverse events were predominantly mild. Disease clearance, assessed by the cumulative incidence of complete molecular remission, peaked at day 700, reaching 74% in the preemptive and 13% in the salvage setting. The five-year progression-free survival was 50% overall and highest (69%) in pediatric acute myeloid leukemia. The five-year overall survival (OS) was 71% in the consolidation, 61% in the preemptive, and 20% in the salvage setting. Multivariable analysis demonstrated significantly lower relapse rates with Campath compared with ATG, superior OS in myeloid malignancies, and reduced IL15-CIK efficacy in advanced disease. The median follow-up was 7.3 years. CONCLUSION IL15-CIK monotherapy is feasible and safe and demonstrates promising relapse-preventive activity after hematopoietic stem-cell transplantation. Clinical outcomes are strongly influenced by disease burden at treatment initiation and previous serotherapy, supporting optimized patient selection and timing in future post-transplant immunotherapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationInterleukin-15Cytokine-Induced Killer CellsLeukemiaHumansMaleFemaleChildAdultAdolescentMiddle AgedChild, PreschoolProspective StudiesTransplantation, HomologousYoung AdultRemission InductionPilot ProjectsGraft vs Host DiseaseAgedInfant

Substanzen

Interleukin-15IL15 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany.
  • Institute for Experimental Pediatric Hematology and Oncology (EPHO), Frankfurt, Germany.
  • Medical Clinical II, Goethe University Frankfurt, Frankfurt, Germany.
  • University Children's Hospital, Heidelberg, Germany.
  • Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
  • Johannes Gutenberg-University Mainz, III. Department of Medicine, Germany.

ORCID-Profile: Eva Rettinger, Dirk Heckl, Martin Hutter, Gesine Bug, Johann Greil, Roland Meisel, Eva Maria Wagner-Drouet, Hubert Serve, Jan-Henning Klusmann, Thomas Klingebiel

Zitieren

APA

Rettinger, E., Heckl, D., Hutter, M., Salzmann-Manrique, E., Luedtke, M., Huenecke, S., Bremm, M., Cappel, C., Bug, G., Greil, J., Meisel, R., Wagner-Drouet, E. M., Serve, H., Güngör, T., Klusmann, J. H., Klingebiel, T., Bader, P., & Bonig, H. (2026). First-in-Human Study of IL15–Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. Journal of Clinical Oncology, 44(14), 1323-1336. https://doi.org/10.1200/jco-25-01966

Vancouver

Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, et al. First-in-Human Study of IL15–Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. Journal of Clinical Oncology. 2026;44(14):1323-1336. doi:10.1200/jco-25-01966

BibTeX
@article{Rettinger2026,
  author = {Rettinger, Eva and Heckl, Dirk and Hutter, Martin and Salzmann-Manrique, Emilia and Luedtke, Marie and Huenecke, Sabine and Bremm, Melanie and Cappel, Claudia and Bug, Gesine and Greil, Johann and Meisel, Roland and Wagner-Drouet, Eva Maria and Serve, Hubert and Güngör, Tayfun and Klusmann, Jan-Henning and Klingebiel, Thomas and Bader, Peter and Bonig, Halvard},
  title = {First-in-Human Study of IL15–Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {14},
  pages = {1323--1336},
  doi = {10.1200/jco-25-01966}
}
Kostenlos starten →